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Edited Transcript
This conversation was recorded on February 9, 2021.
DR. RAMIREZ
(1) Thank you for coming today to this session of
COVID-19 Research Conversations. Today I have the
tremendous pleasure to have this conversation with Dr.
Toni Torres. Toni, like other members of this conversa-
tion group, has been a friend of mine for many years,
and I want to ask Dr. Torres to give us a brief introduc-
tion to himself. Toni?
DR. TORRES
(2) Thank you very much, Julio. I’m very glad to be
here sharing this webinar with you; thank you for invit-
ing me. My name is Antoni Torres; I am a Professor
of Pulmonology and Critical Care at the University of
Barcelona, and a researcher of respiratory infections for
many years. So, it’s my pleasure.
DR. RAMIREZ
(3) Thank you, and again, following the theme that we
have in these conversations, first I will ask Toni to give
us a little bit of an overview of what he considers to
be the lessons learned in this presentation, “The Year of
Living Dangerously,” and after his presentation, we’re
going to discuss a little bit of what he’s doing now. And
then, we’re going to move to the second part of the
discussion, which will be how he sees COVID in 2021.
Toni, do you want to start with your presentation?
DR. TORRES
(4) Thank you very much. Well, this is the title that I
chose because I remember a film of this title featuring
Mel Gibson. Well, I liked the film and I like the title be-
cause this is true: a very, very difficult year. I divided
my content into my personal experience, what we did
in research, and what we did in education. Personal ex-
perience: I have some personal thoughts, and I want to
tell you the case of my brother-in-law and some fights
in the hospital—it’s very interesting, but we can discuss
this later.
(5) Look at what happened in 1918 in Spain, dur-
ing the so-called—or wrongly called—“Spanish” in-
fluenza. This1 is from Burgos, a city in the middle of
Spain, and these were the recommendations: the virus
was “transmitted by small particles of saliva when talk-
ing or coughing,” “avoid poorly ventilated places,”
“intense house cleaning,” “follow medical advice and
avoid ignorant recommendations such as smoking and
drinking alcohol.” And this was written in this official
bulletin on October 4, 1918.
(6) Personal thoughts: this quote from Pasteur came to
me that I learned many years ago, and it made an im-
pression on me: “Microbes will have the last word.”
And I think this is true; I always thought that, and
that’s one of the reasons that I dedicated my life to
investigating infections, respiratory infections in this
case. Secondly, reflect that what happened in China
was neglected. And why? I think we had the infor-
mation in December, January, even February; we could
have done a lot. We did intense preparations, for exam-
ple, for SARS; I remember many, many meetings and
many protocols, and SARS never came to Spain. And
in this case, we did not do that. And then finally: Lom-
bardia is very close. Why they did not lock down the
frontiers until it was too late? We saw the cases in Lom-
bardia; I cannot understand that.
(7) Let’s take the case of my brother-in-law, which was
very typical because health care providers had no expe-
rience with COVID at the time. Well, he was one of the
first—he got COVID the third week of March. He’s the
director for an institution for mental discapacities, the
Fundación Catalonia, and there was an outbreak there.
He was diagnosed because he was in the foundation,
not through public health; the public health system was
failing. He had persistent fever at day 8 with cough. I
recommended a chest X-ray first, which was normal,
and then immediately, because I read the papers from
China, I ordered a CT scan, according to Chinese lit-
erature, and the CT scan showed bilateral infiltrates.
The conclusion of the radiologist was COVID in reso-
lution. My brother-in-law called me and said, “I am
okay because it’s in resolution,” and I said, “no, you
have to go immediately to the hospital.” And then,
for that reason—among others—he was not admitted
to the hospital, even with the CT scan; it was unbeliev-
able. And finally a friend of mine, who is running a
private institution here in Barcelona, admitted him, but
he almost died.
(8) Continuing my personal thoughts—and this very
sad—there were fights in the hospital. Infectologists
and the people of the global health department seized
power without consulting with pulmonologists, and
pulmonologists only were called after two weeks and
a lot of admissions, just as partners. Protocols were
changed constantly based on poor and small obser-
vational studies; I was not managing those protocols.
And they changed from hydroxychloroquine to hy-
droxychloroquine plus azithromycin plus remdisivir,
etc., etc. I never have done that in my practice. I
know that they had nothing to go on, but you have
to be very careful. And then finally, the case of cor-
1See RTVE “Yes, the image about the ‘Spanish flu’ of 1918 that circulates on social networks is real” [in Spanish] (https://www.rtve.es/noticias/
20200507/imagen-gripe-espanola-1918-archivo-burgos/2013540.shtml)
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ticosteroids is very clear; corticosteroids were forbid-
den in the hospital because of the examples of SARS
and metapneumovirus, even the guidelines of the Sur-
viving Sepsis Campaign, and I think probably the the
CDC or something—I don’t remember—but corticos-
teroids were forbidden. But then clinicians started to
use corticosteroids, and they observed that in some pa-
tients, corticosteroids were effective. And then, finally,
the studies came, and this is one of standard treatments
now; we cannot cure all of our patients, but corticos-
teroids work pretty well.
(9) Another problem: we ran out of protective equip-
ment. That was terrible, and for that reason, many,
many health personnel got infected. And then we had
to buy this equipment from China, mainly through
Spain, through the European Union—this is another
problem to discuss, and it’s very, very complicated.
(10) These are the hospitalized patients in Hospital
Clı́nic Barcelona up to July—of course, now we have
more—3543 patients and a total mortality of 8% over-
all (ward and ICU), and the mortality of patients in the
ICU was around 30%; you will see that later on. And
this is the evolution of the beds occupied in interme-
diate care units and in the ICU Figure 1; the crest on
the left is the peak of the pandemic. And then we had
a period of stability during the summer, but then in in
September, it started again and is increasing. And now
we are really in the third wave; 70% of the ICU beds in
our hospital and in other hospitals are full of COVID
patients. And this was due to inconsistent measures
on some holidays that we had in December: the 8th
and 9th because it’s a national holiday, and then after
Christmas. We can talk about Christmas later on; this
is important.
(11) Research: what I did with research was to put all
of my research group to work collecting COVID data,
including data for ECMOCARD (probably you know
of ECMOCARD—it’s an international consortium; one
of the leaders was previously my fellow—Gianluigi Li
Bassi—and the senior leader is John Fraser), and they
were collecting data from home. But I received a threat-
ening call from one of my colleagues (I will not say their
name, but this was the reality). He said, “you have to
stop collecting data because you are not allowed to do
that.” Of course, I went first to the ethical committee
and ECMOCARD, and in the next story, I will tell you
about the IRB. And I was called to a committee in the
hospital of the ICU directors of the several ICUs, and
I had to explain everything that I was doing. Unbe-
lievable. And this threatening call was from one of my
colleagues in this department because I had the capa-
bility through the people in my group to collect many,
many data.
(12) But fortunately, I received another call at night,
at the end of March, from the director of a network in
Spain, which is called Fever (might be you’re aware of
them, Julio). And he told me, “Toni, there will be an im-
portant call from the Central Government for Research,
and I would like you to prepare a study to apply for a
grant.” And I thought that I should do that, because I
wanted to do something for my patients, for my group,
and for the society, and this was the opportunity. And
then, at the beginning—this is important—some of my
people in the research group lost control because they
just wanted the glory. And what was the glory? The
glory is to sign first one of the 90—I think there are
90,000 or more, 100,000 manuscripts now—and I said,
“being cited is not what matters; this is very good, but
nothing is going to change with that. I think it’s bet-
ter to do a good study.” And then I applied as a PI
for this institution, Instituto de Salud Carlos III. What I
wanted to do is to study the risk factors, personalized
prognosis, and 1-year follow-up in patients admitted
to Spansih intensive care units with COVID-19 infec-
tion. This project is called CIBERESUCICOVID, and I
got this grant for e1,750,000, which for Spain is prob-
ably one of the highest, and for my career as well; this
was a lot of money.
(13) The project hypothesis at that time—this was the
end of April—was that a significant percentage of hos-
pitalized patients with COVID-19 are expected to re-
quire admission to the intensive care unit (20%), need
mechanical ventilation (80%) and receive ECMO treat-
ment (5%). And I think that these figures have proved
to be true, at least in the first peak. And patients
who survive the acute ICU episode will have a one-
year cumulative incidence of death of 40%. And those
who still survive will have functional respiratory se-
quelae, cardiovascular events, and poor quality of life
at six months. I think that this has also proven true,
although I don’t know about the figure of 40%. It
was a prospective/retrospective multicenter observa-
tional study of patients admitted to Spanish ICUs—
only Spanish ICUs—and all patients eligible in each
ICU are recruited when possible. So, we are recruit-
ing all the patients. At that time, we said 50 Spanish
ICUs; now we have 65. We said 5,000 patients for the
clinical study; now, we have 6,000, as well as 1,000 pa-
tients for epigenetic/biomarker studies—we collected
samples when possible in the first 24–48 hours, and
the clinical data will be analyzed using artificial intelli-
gence for the prognosis algorithms.
(14) This was the situation in November: more than
5000 patients included, 2,100 completed patients, and
now these figures are 6,000 and 2,500. And now we
have more than 65 centers with access to a REDCap sys-
tem to include the data. Here is some of the informa-
tion Table 1. Now, we are writing a paper with many
more patients. And importantly, we collected this data
sequentially, which is missing in most of publications;
we have data on day 1, on day 3, the intermediate point,
the day of extubation, the day of ICU discharge, the day
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Table 1. Baseline characteristics.
All (n=1318) Alive (n=957) Dead (n=361)
Sex, male 929 (70.49%) 663 (69.28%) 266 (73.68%)
Age, years 62.0 [53.0–70.0] 60.0 [50.0–67.0] 68.0 [62.0–75.0]
BMI, kg/m2 28.65 [26.1–32.4] 28.65 [25.9–32.6] 28.69 [26.5–32.3]
Co-existing disorders, n (%)
Hypertension 616 (46.7%) 382 (39.2%) 234 (64.8%)
Chronic heart disease 183 (13.8%) 103 (10.7%) 80 (22.6%)
Diabetes 307 (23.3%) 181 (18.9%) 126 (34.9%)
Chronic pulmonary disease 154 (12.0%) 75 (8.0%) 80 (22.2%)
Chronic kidney disease 90 (6.8%) 37 (3.9%) 53 (14.7%)
Previous 30 days admission, n (%) 35 (2.7%) 16 (1.7%) 19 (5.4%)
Figure 2. Age distrubtion of patients, dead and alive.
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of hospital discharge, and the day of hospital admis-
sion. In this population, alive and dead, you can see
the sex, and nothing is very different compared to what
you have seen—and the comorbidities as well; you are
very aware of that. And then you can see the distri-
bution of age Figure 2; of course, the older people are
dying more. And most of the patients were admitted to
the ICU with bilateral infiltrates Figure 3 and ARDS.
(15) There was not much difference between alive and
dead patients when comparing leukocytes, lympho-
cytes, neutrophils, C-reactive protein, LDH, ferritin,
and D-dimers at hospital admission. ICU admission
versus day 3 is what I am looking at now, and the pa-
per will will deal with this difference. What we found
was that PaCO2, lactate, and urea were all higher in
dead patients than alive Table 3. When we looked at
the mechanical ventilation parameters, the ventilatory
ratio—a combination of the minute ventilation and the
PaCO2—was one of the significant variables Table 4.
The compliance was as well—lower compliance in the
patients who died at both day 1 and day 3. And you can
see here no difference in peak pressure or driving pres-
sure, but more prone positioning for those who died;
this is because they were more sick.
(16) These are the treatments (Figures 4 and 5). You
can see here a lot of treatments, especially in the be-
ginning (hydroxychloroquine was withdrawn from the
project). And you see what happened with corticos-
teroids: no difference comparing alive to dead in our
population. And this is the hospital during the project
and what happened to the patients Figure 6. As you
know, median symptom onset was six days (dead) ver-
sus seven days (alive). I think that in some studies,
the median time is shorter in patients with worse prog-
noses. For those who were alive, ICU discharge oc-
curred at a median of 12 days, end of mechanical ven-
tilation at a median 14 days, and hospital discharge at
a median 26 days.
(17) The complications: mainly, you can see here Ta-
ble 5 that the complications are not very different, but
acute renal dysfunction was higher in patients who
died. This is something that has been observed before.
Infectious complications: this is an interesting point—
that in our study with this population, we could not
find a significant difference in the percentage of pa-
tients alive or dead in terms of pulmonary, genitouri-
nary, and bloodstream infections. There were a lot
of patients with bacteremia in both arms, and Pseu-
domonas, Enterococcus, Staphylococcus aureus, MRSA and
Candida albicans were the most frequent isolated mi-
croorganisms. And this is the the final data Figure 7,
showing that 73% of patients were discharged alive—
remember that all these patients went to the ICU. The
total death rate was 27%.
(18) Outcomes in relation to interventions: you can
see here that there were no differences between alive
and dead patients regarding prone positioning Figure
8 or tracheostomy Figure 9, but there was for renal re-
placement therapy Figure 10. There was no difference
in ECMO Figure 11, but we didn’t have a lot of pa-
tients at that time. Now, we have more and—this is
interesting—this is data Figure 12 that includes more
patients regarding what happened on day 1, day 3 and
day of extubation (extubation includes death), and you
can see here that the patients who were alive had in-
creased lymphocytes on day 3, the same for platelets,
and no difference in in D-dimers. There was a dif-
ference in decreasing ferritin in patients that are alive.
And—this is important, because there is a controver-
sial issue—interleukin 6 in blood suffered a tremen-
dous increase at day 3 compared to day 1 in the ICU,
and most of the patients were mechanically ventilated
on day 1, indicating that after mechanical ventilation,
something goes wrong in some patients that dramati-
cally increases interleukin 6. Finally, CRP is decreased
in both dead and alive patients at day 3 after ICU ad-
mission.
(19) This is one paper that we published from our
study, looking at SARS-CoV-2 RNAemia and the viral
RNA load in plasma.[2] And you can see here Figure
13—and this is something that has been described as
well—that viral RNA load in plasma is associated with
critical illness and dysregulated response in COVID-19.
(20) Now some words about the follow- up of COVID.
I am in charge of follow-up with health professionals
that go astray. And really, it is very sad to see the
long-term consequences that I observe in some of them.
And I realized that I cannot do almost anything for
them. And I thought, this is a very poor reward for
them—this is something for the discussion section—
because they risk their lives, and the reward was 1,500
viewers—in the last journal in the summary, depend-
ing on the category.
(21) Education: education was a real challenge. I am
in charge of the respiratory diseases curriculum at the
University of Barcelona, and I had to reorganize all
the education for students in respiratory diseases. So,
we have to record all the lectures; they could not do
practical education; over the last year, we found a sys-
tem of splitting students into small groups; we had
many, many talks and webinars, and probably the con-
sequence of this will be a shift in the paradigm of the
presence of the professional in the lecture.
(22) Conclusions: of course, one year living in dan-
ger, and we still are in danger; we weren’t prepared
for this; it’s been a great human and economical disas-
ter, and the economic consequences will be disaster—
are disaster—in Spain. And it is amazing that some
politicians voted for death; they did not vote for life.
And now in Spain, the elections for the Parliament of
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Figure 3. Frequency of lung infiltrates detectable via x-ray.
Table 2. Hospital admission.
All (n=1318) Alive (n=957) Dead (n=361)
Leucocytes (109/L) 7.14 [5.23-9.86] (877) 7.0 [5.19-9.82] (643) 7.48 [5.5-10.07] (234)
Lymphocytes (109/L) 0.8 [0.55-1.06] (866) 0.8 [0.57-1.05] (637) 0.76 [0.5-1.1] (229)
Neutrophils (109/L) 5.8 [4.14-8.42] (583) 5.7 [4.16-8.4] (440) 5.95 [4.1-8.59] (143)
C-reactive protein 3.18 [1.38-14.16] (826) 2.99 [1.29-13.1] (606) 3.34 [1.6-16.25] (220)
LDH 410.0 [302.75-524.0] (544) 407.0 [304.0-519.0] (417) 443.0 [299.0-585.5] (127)
Ferritin 1077.0 [526.0-1944.0] (313) 1036.5 [531.25-1991.5] (248) 1131.0 [488.0-1619.0] (65)
D-Dimer 0.69 [0.4-1.22] (626) 0.68 [0.4-1.2] (473) 0.72 [0.43-1.28] (153)
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Figure 4. Anti-COVID-19 treatments.
Figure 5. Adjuvant therapies.
Table 5. Complications.
All (n=1318) Alive (n=957) Dead (n=361)
Pneumothorax 84/1318 (6.37%) 41/957 (4.28%) 43/361 (11.91%)
Pulmonary Embolism 135/1318 (10.24%) 107/957 (11.18%) 28/361 (7.76%)
Cardiac ischemia 61/1318 (4.63%) 33/957 (3.45%) 28/361 (7.76%)
Myocarditis 21/1318 (1.59%) 13/957 (1.36%) 8/361 (2.22%)
Heart attack 11/1318 (0.83%) 7/957 (0.73%) 4/361 (1.11%)
Acute renal dysfunction 407/1318 (30.88%) 215/957 (22.47%) 192/361 (53.19%)
Hepatic dysfunction 452/1318 (34.29%) 331/957 (34.59%) 121/361 (33.52%)
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Figure 6. Supportive treatments.
Figure 7. Main outcomes—patient journey.
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Table 6. Infectious complications.
All (n=1318) Alive (n=957) Dead (n=361)
Infectious focus
Pulmonary 469 (35.6%) 328 (34.3%) 141 (39.1%)
Genitourinary 210 (15.9%) 161 (16.82%) 49 (13.6%)
Bloodstream 277 (21.0%) 177 (18.5%) 100 (27.7%)
Skin and soft tissue 54 (4.1%) 39 (4.1%) 15 (4.2%)
Gastrointestinal 17 (1.3%) 13 (1.36%) 4 (1.1%)
Osteoarticular and bone 1 (0.08%) 1 (0.1%) 0 (0%)
Infectious agent
Pseudomonas aeruginosa 181 (13.7%) 125 (13.1%) 56 (15.5%)
Enterococcus 139 (10.5%) 104 (10.9%) 35 (9.7%)
Staphylococcus spp (no S. aureus) 111 (8.4%) 77 (8.1%) 34 (9.4%)
Candida albicans 90 (6.8%) 50 (5.2%) 40 (11.1%)
Staphylococcus aureus 79 (6.0 %) 55 (5.8%) 24 (6.7%)
Figure 8. Outcomes in relation to prone positioning.
Figure 9. Outcomes in relation to tracheostomy. Figure 10. Outcomes in relation to renal replacement therapy.
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Figure 11. Outcomes in relation to ECMO.
Catalonia will be February 14, and the Catalonian gov-
ernment decided to postpone these elections—imagine:
the elections of a country of 8 million persons, but the
Spanish government refused the change of elections.
And now we’ll have elections for politicians’ interest—
other people that voted for death. But on the other
hand, it was an opportunity for research and educa-
tion and an opportunity to know solidarity and non-
solidarity. Thank you for very much for this opportu-
nity, it was really very nice to be with you. God bless
you.
DR. RAMIREZ
(23) This is so interesting that this is a quote unquote
“respiratory infection,” but your presentation is a com-
prehensive experience of essentially all your life as an
investigator and so much social impact of this disease
at every level. So many questions I would like to ask
you, but I want to ask you only one or two questions
from the science of your research, and then I would
like to move to the second part. Very impressive—the
data on on interleukin six, where you see this separa-
tion of the high levels of interleukin 6 in patients that
die and low levels in patients that are alive. And this
also brings up the tocilizumab studies and all the ways
that we tried to block interleukin 6, and it seems to be
that blocking interleukin 6 didn’t give us the effect we
were looking for. What do you think is its role? What
is interleukin 6 doing?
DR. TORRES
(24) I think—well, the role or the cause of this in-
crease?
DR. RAMIREZ
(25) Yes, well, both: is interleukin 6 the chicken or the
egg? What do you make of this in the pathophysiology
of this disease?
DR. TORRES
(26) Well, I think despite the controversies about the
cytokine storm, initially, interleukin 6 overall is not
so high compared to ARDS, or sepsis of community-
acquired pneumonia, for example; with sepsis, this is
clear. But something happens in the middle; after 48
hours of mechanical ventilation, something happens—
I don’t know the reason—and whatever it is, it’s very
bad, because then the host cannot control this inflam-
mation, and inflammation is bad for the lungs and for
all the organs. And I want to look at whether this is
a cause of wrong mechanical ventilation. This is one
of my hypotheses, but I’m not sure of it. I have the
data; I have to see if these patients have a different tidal
volume—have a non-protected ventilation, for exam-
ple. This could be one of the reasons; otherwise I don’t
understand because these patients are treated equally. I
have to look at the treatments as well. I have to look at
several things, but something is wrong between days 1
and 3 that we do or that is genetically marked, perhaps.
I don’t know.
DR. RAMIREZ
(27) But it’s important that you’ve been thinking about
this, and I can see your thought process. Do you think
that somehow—the quote unquote “respiratory fail-
ure” of COVID and the pathophysiology at the alveolar
capillary level—do you think that this virus is doing
something different, that they will require a different
type of ventilatory approach?
DR. TORRES
(28) Probably not; the utilitarian approach is protec-
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Figure 13. Viral RNA load in plasma, targeting the N1 region (left) and the N2 region (right), in the three groups of patients. Results are provided
as copies of cDNA per mL of plasma.
tive ventilation for everybody, but this is not so dif-
ferent because what is protective ventilation? This in-
cludes a low tidal volume less than 6 cc/kg and a
plateau pressure of 30. So, again, we have to look at the
deltas, because with the deltas we will know, but not
all the patients are similar. These patients are elderly;
they have comorbid conditions—COPD for example—
and then not everybody has the same vasal compliance
in the lung.
(29) And then, maybe we are doing a harmful ventila-
tion in some of them because the compliance is differ-
ent; the compliance of a young person is not the same as
that of the elderly—the vasal compliance—and maybe
what we call “protective” ventilation is not so protec-
tive. This is what we learned from ARDS, but that
was for non-COVID ARDS, and it might be different,
or maybe there is something that is genetically already
programmed. This is something we’re looking into, but
again, to understand what happens, we need to know
the difference between day 1 and day 3 or day 4. This
is part of the point of my study because at day 3 of me-
chanical ventilation in a patient with ARDS, you still
can do something; you can modify something; you can,
for example, lower the tidal volume, try to decrease
the plateau pressure, or even protective extracorporeal
membrane treatment stimulation. Why not?
DR. RAMIREZ
(30) Very good; very interesting. Congratulations on
the grant, by the way. Another question: what are you
seeing in your post-COVID follow-up clinic in health
care workers? Because there’s so much—in every city
all over the world now, we have developed these post-
COVID clinics as we see the consequences.
DR. TORRES
(31) Well, when I see these patients or phone them,
those who are persistently sick complain of fatigue, a
general tremendous fatigue, very similar to what I have
seen in patients whom I have diagnosed with chronic
fatigue syndrome in the past. They do something ap-
parently very simple, and then they have to rest. Oth-
ers have cardiac alterations, arrhythmias that are diffi-
cult to manage. And importantly, they complain of a
strange pain in the thorax; this is also very common.
And since I have seen a couple of patients with very
clear pericarditis, I suspect the virus affects the peri-
cardium and the pleura. Do you remember the concept




(33) Okay, I think this is a viral pleuritis or pericarditis,
with this difficult to understand pain that sometimes is
in relation to the moment, sometimes not. But I don’t
think that this is dangerous; this is going to disappear
with time, similar to the Bornholm disease.
DR. RAMIREZ
(34) Very interesting. Moving now into the second
part of this conversation, which is how do we see
COVID-19 in 2021. We discussed health care work-
ers with post–COVID-19 syndrome. What is your feel-
ing about health care workers in Spain experiencing
this because there’s this persistent pressure with more
COVID cases in the hospital; here in Kentucky, one of
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our lead infectious disease specialists died of COVID.
Then, we have the full spectrum: everybody knows
a health care worker who died; in every hospital, we
have health care workers who died and some with
chronic problems. And everybody knows health care




(36) Then how do you see the impact? And you al-
luded a couple of times to the role of the government;
how do you see the impact in health care moving for-
ward for ICU staff or for anybody in the hospital?
DR. TORRES
(37) Yes, well, first, what I see now in the health care
personnel is irritability and depression. I have seen
some cases of deep depression because this intensity
is impossible to sustain; it’s impossible for the brain to
accept it. And then some of them are very tired and
very irritable, and they cannot sleep well. It’s also very
difficult now to find nurses in Spain. The reason is
that before the pandemic, the Spanish nurses went to
the United Kingdom and to Germany because they are
paid better there, and here it was very difficult for them
to have a fixed position. And so if this is going to be
maintained, this current situation—which is, I suspect,
the case, and we can discuss that later on—it’s going to
be a terrible problem for Spain at least, for sure. The
advantage now is that we are better prepared; we have
more experience. And now, the third wave is going to
be just as bad as the first wave—this is what the data
indicate—but the number of infections is decreasing.
So if this is going to last for some years, it’s going to
be very difficult.
(38) The politicians and educators will have to change
things, perhaps give a rapid formation—rather than
years long—for nurses. A lot of our nurses are from
South America, so there is immigration from South
America to Spain, and from Spain to the north of Eu-
rope. And this is the case with many, many physicians.
And then, when our residents realize that they will be
better paid elsewhere, they leave. I think that politi-
cians should use the funds that the European Union
plans to give us—they told us next June; I don’t under-
stand that. Why next June? Why not now? We need the
money now, not next June. And they will have to invest
in health, in ICU beds, in personnel, and in equipment.
And the society is in favor of that. But I have seen many
bad things from the society as well.
DR. RAMIREZ
(39) You mentioned what happened at Christmas and
other holidays, particularly with young people; the pa-
tients that you see in the ICU are primarily elderly, but
the people in the society who complain that they can’t
go out for tapas and so on are primarily the young peo-
ple. How do you see this moving forward?
DR. TORRES
(40) Well, the mean age is lower now in the ICU; we
are seeing people around 40 years old getting very sick.
But of course, the higher percentage is the elderly pop-
ulation. And these people probably get COVID from
young people enabling the transmission of the disease.
They don’t understand; what I have seen in society is
that they think that they will never get COVID, and if
they ever do get it, it’s not going to be dangerous for
them. And for that reason, what they want is to so-
cialize, despite all they are seeing. We have had about
55,000 deaths in Spain since the beginning, in a coun-
try of 36 million. This is a lot, but they don’t care. I
remember that a couple of weeks ago, I went out for
dinner (sitting outside and everything), and the people
there were not wearing masks. So, I told them, “please
use the masks.” And they were very angry with me,
and I just had to leave.
(41) And then Christmas. Christmas was a problem
because it is so ingrained in the brain of the Span-
ish people—the holidays, not the religion, the holi-
days. Christmas means shopping, means stop working,
means vacation. That’s the young people; they wanted
to do all that. On the other hand, it is very difficult to
explain to the elderly—for example, my mother is 93,
and my mother-in-law is 92—it was very difficult for
them to understand that we were not going to celebrate
anything this year. And a lot of people who celebrated
got infected or died. And now we are seeing the conse-
quence of of that. This was Christmas.
DR. RAMIREZ
(42) This is the society. Now, going back to another
topic that you mentioned: the change in education. Ev-
erybody agrees that probably, this online form of ed-
ucation is here to stay, but at some point, you men-
tioned that the professional will no longer be in the
classroom? You’re in charge of education at the Uni-
versity of Barcelona; what will medical education look
like moving forward?
DR. TORRES
(43) I think that we will keep the lectures online, but
we will do seminars with the professional present to
solve doubts, for example. I think this is going to be
much more efficient, probably, because if you record
the lecture, you use the same slides that you would use
in the class. And if the students do not ask questions
during the lecture, then I think that we can save time—
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even using that time to prepare the lectures better—and
then meet the students in seminars or small groups to
resolve doubts or to do in-depth review of other as-
pects.
DR. RAMIREZ
(44) Yes, some of these changes are here to stay.
DR. TORRES
(45) I think so. Importantly, we we are not going to
travel anymore for lectures, probably. And this is good
because remember: the last time I met you was in Saudi
Arabia, I think, or in Dubai; do you remember? Trav-
eling to the other side of the world to give a lecture
that you can do online, and then you can answer all
the questions perfectly, is a waste of time. For us, this
is a release.
DR. RAMIREZ
(46) No question. And then going back to COVID, you
mentioned that it will likely continue for a couple of
years, while a lot of people have been saying that they
were looking at this year as the end of COVID. But
with all the variants that we have from South Africa,
Brazil, and England, you could argue that this may con-
tinue for some time. You mentioned that steroids is one
method of treatment, but it’s not too impressive. What
do you think a more effective treatment will be: an an-
tiviral, blocking the immune response, improving ven-
tilation?
DR. TORRES
(47) Steroids are useful for some of our patients, and
we see a lot of patients that improve rapidly. I think
that we need to know more about phenotypes—in
which phentoypes steroids are effective or not. This
is important; we don’t know the answers. But steroids
work in most of the population, and you have seen that
there is a difference between alive and dead patients in
our population in relation to corticosteroids. Second,
antivirals: we need new antivirals. I don’t know if you
saw the news yesterday; there is a Spanish investigator
at Mount Sinai, who has come out with a new antivi-
ral 100 times more potent than remdesivir that clears
COVID completely in mice.2 We need something like
that in the first period of the disease. And then, in the
period of inflammation, of course, we need to use spe-
cific anti-inflammatory drugs to block the inflamma-
tory response without being harmful for the patient. If
tocilizumab is effective, nevertheless, what we’re see-
ing with tocilizumab is many more infections. So we
need antivirals from the very beginning—new antivi-
rals.
DR. RAMIREZ
(48) And then, before I let you go, I need to ask you
what happened in Spain with the vaccines.
DR. TORRES
(49) Well, at the very beginning, without the input
of pharmaceutical companies, I applauded them, but
I think that I was probably wrong; the interest of the in-
dustry and money is always beneath the surface. Phar-
maceutical companies have done a lot of good because
they provide a lot of input for trials, which is very help-
ful, but now what is happening with vaccines? We
aren’t getting the vaccines now because AstraZeneca
says that they have changed the deal with the Euro-
pean Union, and Pfizer has reduced production—what
is happening? Does this mean that these industries
are in association with other countries? The European
Union is very angry with AstraZeneca. We need to
know what is behind this.
DR. RAMIREZ
(50) Yes, yes, well, transparency has not been really—
DR. TORRES
(51) No, although a lot of people from the industry are
very honest, of course.
DR. RAMIREZ
(52) I will say that regarding some of these transac-
tions at every level—
DR. TORRES
(53) Well, these are very high level transactions. I just
received one dose of the vaccine, and I have to receive
the second next Tuesday, but then they were saying on
the radio this morning that it is not certain that we have
vaccines for the second dosage.
DR. RAMIREZ
(54) Now, another question: every week a new trial
is announced, all the way through vaccine studies to
antiviral studies to immunomodulatory studies. How
do you decide what trials to do at your institution? I
was talking to Mike Niederman the other day, and they
have put together a committee to decide who is doing
what trial.3 I found this interesting because, at least in
my experience, we’ve always had the industry contact
one investigator, and the investigator decides yes or no.
2Plitidepsin, developed by Adolfo Garcı́a-Sastre et al. at Mount Sinai University, New York.[3]
3See Ramirez JA, Niederman MS, Schenck EJ. International Respiratory Infections Society COVID Research Conversations: Podcast 2 with Dr.
Michael S. Niederman and Dr. Edward J. Schenck. Univ Louisville J Respir Infect 2021; 5(1): Article 6.
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DR. TORRES
(55) For us, this is a still individual; the industry con-
tacts the investigator. If you decide to go ahead, there
is a committee in the hospital who have to be informed,
but you are free to send the protocol to the IRB. Espe-
cially at the beginning, it was very individual; now it is
better organized, and there is a committee that decides
whether the hospital is going to participate or not.
DR. RAMIREZ
(56) This is a new way to look at all this because, again,
traditionally the industry selected one investigator, and
they decided, but of course, now we have to develop
more and more committees to organize all the research
activities because we are going to keep doing research
on COVID for a long time.
DR. TORRES
(57) I agree with having committees to decide because
even these committees are experts; they can decide on
the most interesting trials or what will potentially be
more effective for the patients at the end because there
are some trials that are going to fail or will be very dif-
ficult to understand.
DR. RAMIREZ
(58) Going into clinical trials—we’ve never used corti-
costeroids for pneumonia before COVID-19.
DR. TORRES
(59) No, never. I think this is a new invention.
DR. RAMIREZ
(60) And there’s a lot of discussion with people who
are doing trials in pneumonia—these new outcomes
point this way or that—
DR. TORRES
(61) Well, pneumonia was managed by pulmonolo-
gists, and by intensivists when the pneumonia was se-
vere, but not by infectologists. You are the exception—
you funded CAP research, and there is a school of CAP
study—but the others are pulmonologists, in Europe as
well and in Spain. Now, infectologists and epidemiol-
ogists are making decisions, and they don’t typically
know about pneumonia. And that’s what this is; this is
a viral pneumonia.
DR. RAMIREZ
(62) Yes, that’s plain and simple; it’s a viral pneumo-
nia.
DR. TORRES
(63) But then, we have to use our experience with
pneumonia and what we learned.
DR. RAMIREZ
(64) In our hospital—I don’t know what your experi-
ence has been—a significant percentage of the patients
do not have pneumonia; we consider them COVID pa-
tients because they have a positive PCR, but the rea-
son for admission was something that is not related to
COVID. But then they are enrolled in COVID studies.
Should it be the case that to be in a COVID study, you
have to have pneumonia?
DR. TORRES
(65) I think so, yes—admitted for pneumonia. The tri-
als should not include patients with another disease
solely because they have a positive COVID PCR be-
cause this is going to bias the results. The problem is
that they are using this classification for trials, and if
you look at the scores of 30-day mortality, still PSI in
COVID is one of the best, very similar to others that
combined several things together. You can’t just use
PCR; you have to use PSI. It’s a viral pneumonia.
DR. RAMIREZ
(66) Okay, well, we’ve been talking for one hour. As
always, it has been a pleasure to have you and to hear
your experiences. Probably, we will do this again at
some point as your research evolves.
DR. TORRES
(67) Keep very safe and healthy.
DR. RAMIREZ
(68) Okay, we’ll keep in contact. And I want to thank
everybody that is listening to these conversations. And
I will always mention that if someone has any specific
question for you, Toni—
DR. TORRES
(69) Send me an email, yes—no problem.
DR. RAMIREZ
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